¥4324 -34.0 -0.8%
Last Trade - 12/04/21
| Market Cap | £47.29bn |
| Enterprise Value | £44.85bn |
| Revenue | £5.24bn |
| Position in Universe | 14th / 3900 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 498,840 | 491,781 | 534,199 | 579,787 | 686,184 | 786,946 | 834,942 | 824,456 | +9.5% | ||
| +19.8 | -12.2 | +35.4 | +27.0 | +70.3 | +36.2 | +16.1 | -5.83 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the research, development, manufacture, sale, import and export of pharmaceutical products. The pharmaceutical products and medical devices for patients include ACTEMRA, Avastin, ALAGLIO, Aresensa, Kadosaira, Gazaiba, Seruseputo, Zeruborafu, Zeroda, Taruseba, Tecentoriku, Pajeta and other products. The products are mainly applied to the treatment of cancer, kidney diseases, kidney transplantation, bone and joint diseases such as rheumatoid arthritis, osteoporosis, knee osteoarthritis and locomotive syndrome, influenza, hemophilia and other diseases. The Company is also engaged in the provision of management services, transportation and storage services, as well as drug information literature research services. The Company operates within the domestic market and to overseas markets, including Switzerland, United Kingdom, Germany, France, China, Singapore, Korea and the United States.
| Last Annual | December 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | March 8, 1943 |
| Public Since | March 3, 1956 |
| No. of Shareholders: | 34,921 |
| No. of Employees: | 7,555 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Nikkei 225 , Nikkei 300 , |
| Exchange | Tokyo Stock Exchange |
| Shares in Issue | 1,643,871,081 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 15F Nihonbashi Mitsui Tower,2-1-1 Nihonbashi-Muro-machi, CHUO-KU, 103-8324, Japan |
| Web | https://www.chugai-pharm.co.jp/ |
| Phone | +81 3 32816611 |
| Contact | Kazuya Usuda (Director of Finance & Accounting) |
| Auditors | KPMG AZSA LLC |
As of 12/04/21, shares in Chugai Pharmaceutical Co are trading at ¥4324, giving the company a market capitalisation of £47.29bn. This share price information is delayed by 15 minutes.
Shares in Chugai Pharmaceutical Co are currently trading at ¥4324 and the price has moved by -5.31% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Chugai Pharmaceutical Co price has moved by -39.43% over the past year.
Of the analysts with advisory recommendations for Chugai Pharmaceutical Co, there are there are currently 0 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Chugai Pharmaceutical Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Chugai Pharmaceutical Co is scheduled to issue upcoming financial results on the following dates:
The Chugai Pharmaceutical Co dividend yield is 1.27% based on the trailing twelve month period.
Last year, Chugai Pharmaceutical Co paid a total dividend of 55, and it currently has a trailing dividend yield of 1.27%. Looking ahead, shares in Chugai Pharmaceutical Co are due to go ex-dividend on 2021-06-29 and the next dividend pay date is 2021-09-01.
Chugai Pharmaceutical Co are due to go ex-dividend on 2021-06-29 and the next dividend pay date is 2021-09-01. The historic dividend yield on Chugai Pharmaceutical Co shares is currently 1.27%.
To buy shares in Chugai Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Chugai Pharmaceutical Co are currently trading at ¥4324, giving the company a market capitalisation of £47.29bn.
Here are the trading details for Chugai Pharmaceutical Co:
Based on an overall assessment of its quality, value and momentum, Chugai Pharmaceutical Co is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Chugai Pharmaceutical Co are currently priced at ¥4324. At that level they are trading at 12.27% discount to the analyst consensus target price of 0.00.
Analysts covering Chugai Pharmaceutical Co currently have a consensus Earnings Per Share (EPS) forecast of 151.592 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chugai Pharmaceutical Co. Over the past six months, the relative strength of its shares against the market has been -23.56%. At the current price of ¥4324, shares in Chugai Pharmaceutical Co are trading at -12.35% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Chugai Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is 33.13. The shares are currently trading at ¥4324.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Chugai Pharmaceutical Co's management team is headed by:
Here are the top five shareholders of Chugai Pharmaceutical Co based on the size of their shareholding:
